Drugs on the Horizon for Treatment of Type 2 Diabetes (Q40467575)

20 September 2017

1 reference

title

Drugs on the Horizon for Treatment of Type 2 Diabetes (English)

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

15 July 2024

1 reference

J. Rachman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7648818

15 July 2024

R. C. Turner

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7648818

15 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=7648818

15 July 2024

publication date

1 June 1995

1 reference

full work available at URL

20 September 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1464-5491.1995.tb00526.x

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1464-5491.1995.tb00526.x

15 July 2024

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

15 July 2024

1 reference

20 September 2017

volume

12

1 reference

20 September 2017

issue

6

1 reference

20 September 2017

page(s)

467-478

1 reference

Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.1995.TB00526.X

Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.1995.TB00526.X

New oral thiazolidinedione antidiabetic agents act as insulin sensitizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.1995.TB00526.X

Effects of alpha-adrenoceptor antagonists on clonidine-induced inhibition of insulin secretion by isolated pancreatic islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.1995.TB00526.X

Adrenergic regulation of insulin secretion during fasting in normal subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.1995.TB00526.X

Imidazoline antagonists of alpha 2-adrenoceptors increase insulin release in vitro by inhibiting ATP-sensitive K+ channels in pancreatic beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.1995.TB00526.X

Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.1995.TB00526.X

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.1995.TB00526.X

Mechanism(s) of the blood glucose lowering action of benfluorex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.1995.TB00526.X

Benfluorex and blood glucose control in non insulin-dependent diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.1995.TB00526.X

21 January 2018

Oral hypoglycemic agents

2

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Acute and chronic effects of hyperglycaemia on glucose metabolism

15 July 2024

3

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Pharmacological approach in the treatment of insulin resistance

15 July 2024

4

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

15 July 2024

Biguanides and NIDDM

6

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Ciglitazone, a New Hypoglycemic Agent: I. Studies in ob/ob and db/db Mice, Diabetic Chinese Hamsters, and Normal and Streptozotocin-Diabetic Rats

15 July 2024

8

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5-[4-(1-Methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), a New Antidiabetic Agent

15 July 2024

9

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats

15 July 2024

10

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Actions of novel antidiabetic agent englitazone in hyperglycemic hyperinsulinemic ob/ob mice

15 July 2024

11

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone.

15 July 2024

12

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

The effect of CP 68,722, a thiozolidinedione derivative, on insulin sensitivity in lean and obese Zucker rats.

15 July 2024

13

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

In vitro studies on the action of CS-045, a new antidiabetic agent

15 July 2024

14

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Pioglitazone Increases Insulin Sensitivity by Activating Insulin Receptor Kinase

15 July 2024

15

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Effect of pioglitazone on insulin receptors of skeletal muscles from high-fat-fed rats

15 July 2024

16

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects

15 July 2024

17

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM.

15 July 2024

18

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Resistance to insulin suppression of plasma free fatty acid concentrations and insulin stimulation of glucose uptake in noninsulin-dependent diabetes mellitus

15 July 2024

24

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance

15 July 2024

25

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Effect of fatty acids on glucose production and utilization in man

15 July 2024

26

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus

15 July 2024

27

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects.

15 July 2024

28

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects

15 July 2024

29

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

THE EFFECT OF NICOTINIC ACID IN DIABETES MELLITUS

15 July 2024

30

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Inhibition of lipolysis by nicotinic acid and by acipimox

15 July 2024

32

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus

15 July 2024

34

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

The effect of acipimox in patients with type 2 diabetes and persistent hyperlipidaemia

15 July 2024

35

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM

15 July 2024

36

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Improvement of glucose tolerance in NIDDM by clofibrate. Randomized double-blind study.

15 July 2024

38

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Effects of bezafibrate on insulin secretion and peripheral insulin sensitivity in hyperlipidemic patients with and without diabetes

15 July 2024

39

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM

15 July 2024

40

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Management of dyslipidemia in NIDDM.

15 July 2024

42

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Inhibition by etomoxir of carnitine palmitoyltransferase I reduces hepatic glucose production and plasma lipids in non-insulin-dependent diabetes mellitus.

15 July 2024

45

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus

15 July 2024

46

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Inhibition of metabolic processes by coenzyme-A-sequestering aromatic acids. Prevention by para-chloro- and para-nitrobenzoic acids

15 July 2024

47

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Inhibition of hepatic glucose production by SDZ 51641

15 July 2024

48

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Natural history of pancreatic islet B-cell function in type 2 diabetes mellitus studied over six years by homeostasis model assessment.

15 July 2024

49

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

The effect of epinephrine on immunoreactive insulin levels in man

15 July 2024

50

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Effect of alpha-adrenergic blockade on insulin secretion in man

15 July 2024

54

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

A role for alpha-adrenergic receptors in abnormal insulin secretion in diabetes mellitus

15 July 2024

56

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Alpha-adrenergic blockade improves glucose-potentiated insulin secretion in non-insulin-dependent diabetes mellitus

15 July 2024

57

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Mechanism of insulin secretion by midaglizole

15 July 2024

59

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Alpha 2-adrenoceptor blockade does not enhance glucose-induced insulin release in normal subjects or patients with noninsulin-dependent diabetes

15 July 2024

62

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

The alpha adrenoceptor antagonist properties of idazoxan in normal subjects

15 July 2024

63

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Effect of an oral α2-adrenergic blocker (MK-912) on pancreatic islet function in non-insulin-dependent diabetes mellitus

15 July 2024

64

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Glucagon-like peptide-I and the control of insulin secretion in the normal state and in NIDDM.

15 July 2024

65

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations

15 July 2024

66

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut

15 July 2024

68

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas

15 July 2024

69

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

15 July 2024

70

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Glucagon-like peptide-1 7-36: a physiological incretin in man.

15 July 2024

71

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes

15 July 2024

72

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine

15 July 2024

73

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects

15 July 2024

74

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

15 July 2024

75

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Glucagonlike peptide I (7-37) actions on endocrine pancreas

15 July 2024

76

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37).

15 July 2024

77

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide

15 July 2024

78

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor

15 July 2024

80

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM

15 July 2024

81

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Mechanism of the stimulation of insulin release in vitro by HB 699, a benzoic acid derivative similar to the non-sulphonylurea moiety of glibenclamide

15 July 2024

82

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM.

15 July 2024

84

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals.

15 July 2024

85

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Basal normoglycemia attained with chlorpropamide in mild diabetes

15 July 2024

86

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Guar and its Effects on Metabolic Control in Type II Diabetic Subjects

15 July 2024

87

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Flattening postprandial blood glucose responses with guar gum: acute effects

15 July 2024

88

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

‘Pharmacological Fibre’-Alpha-glucosidase Inhibition in the Management of Diabetes

15 July 2024

89

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential

15 July 2024

90

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone

15 July 2024

91

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Low-dose acarbose improves glycemic control in NIDDM patients without changes in insulin sensitivity

15 July 2024

92

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

The effect of acarbose on blood glucose profiles of type 2 diabetic patients receiving insulin therapy

15 July 2024

94

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

alpha-Glucosidase inhibition by miglitol in NIDDM patients

15 July 2024

97

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.

15 July 2024

99

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Effect of an alpha-glucosidase inhibitor (BAY m 1099) on post-prandial blood glucose and insulin in type II diabetics

15 July 2024

100

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Primary prevention of diabetes mellitus by prevention of obesity in monkeys

15 July 2024

101

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Drug treatment of obesity in type 2 diabetes mellitus

15 July 2024

102

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Hypoglycemic Action of Fenfluramine in Diabetes Mellitus

15 July 2024

103

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Fenfluramine increases insulin action in patients with NIDDM.

15 July 2024

104

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1-wk treatment with d-fenfluramine.

15 July 2024

105

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

The Effects of Dexfenfluramine on Blood Glucose Control in Patients with Type 2 Diabetes

15 July 2024

107

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Obese patients with type 2 diabetes poorly controlled by insulin and metformin: effects of adjunctive dexfenfluramine therapy on glycaemic control

15 July 2024

108

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Fluoxetine treatment of the obese diabetic

15 July 2024

112

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Fluoxetine in the treatment of obese type 2 diabetic patients.

15 July 2024

113

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Thermogenic and antiobesity activity of a novel beta-adrenoceptor agonist (BRL 26830A) in mice and rats.

15 July 2024

114

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Anti-hyperglycaemic action of BRL 26830, a novel beta-adrenoceptor agonist, in mice and rats.

15 July 2024

115

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Effects of BRL 26830, a novel beta-adrenoceptor agonist, on glucose tolerance, insulin sensitivity and glucose turnover in Zucker (fa/fa) rats

15 July 2024

117

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Anti-obesity and anti-diabetic effects of CL 316,243, a highly specific beta 3-adrenoceptor agonist, in yellow KK mice

15 July 2024

124

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Hypothalamic regulatory peptides and the regulation of food intake and energy balance: signals or noise?

15 July 2024

125

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Altered neuropeptide Y concentrations in specific hypothalamic regions of obese (fa/fa) Zucker rats. Possible relationship to obesity and neuroendocrine disturbances

15 July 2024

126

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Diabetes: The quest for basal normoglycaemia

15 July 2024

127

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement.

15 July 2024

128

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Comparison of two twice-daily insulin regimens: ultralente/soluble and soluble/isophane

15 July 2024

129

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

Islet amyloid formed from diabetes-associated peptide may be pathogenic in type-2 diabetes

15 July 2024

132

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

NovoSol Basal: pharmacokinetics of a novel soluble long acting insulin analogue

15 July 2024

133

1 reference

https://api.crossref.org/works/10.1111/J.1464-5491.1995.TB00526.X

15 July 2024

Identifiers

1 reference

20 September 2017

1 reference